Newsroom | 63580 results
Sorted by: Latest
-
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before de...
-
Araris Biotech AG y Taiho Oncology anuncian la dosificación del primer paciente en un ensayo de fase 1 de ARC-02, un nuevo ADC para el tratamiento del linfoma no hodgkiniano
AU, Suiza y PRINCETON, Nueva Jersey--(BUSINESS WIRE)--Araris Biotech AG, una empresa que desarrolla una cartera diferenciada de terapias basadas en conjugados anticuerpo-fármaco (ADC), y Taiho Oncology, Inc., dedicada al desarrollo y la comercialización de tratamientos innovadores para neoplasias hematológicas y tumores sólidos, ambas pertenecientes al grupo Taiho, han anunciado hoy la dosificación del primer paciente en un ensayo clínico de fase 1 de ARC-02, un conjugado anticuerpo-fármaco dir...
-
Araris Biotech AG e Taiho Oncology annunciano la somministrazione del trattamento al primo paziente in uno studio clinico di fase 1 su ARC-02, un nuovo ADC per il trattamento del linfoma non-Hodgkin
AU, Svizzera e PRINCETON, N.J.--(BUSINESS WIRE)--Araris Biotech AG, azienda che promuove una pipeline diversificata di terapie a base di farmaci anticorpo-coniugati (“ADC”), e Taiho Oncology, Inc., società specializzata nello sviluppo e nella commercializzazione di nuovi trattamenti per neoplasie ematologiche maligne e tumori solidi, entrambi membri del gruppo Taiho, oggi hanno annunciato che il primo paziente ha ricevuto il trattamento in uno studio clinico di fase 1 su ARC-02, un farmaco anti...
-
Araris Biotech AG et Taiho Oncology annoncent l'administration de la première dose d'ARC-02 à un patient, un nouvel ADC pour le traitement du lymphome non hodgkinien, dans le cadre d'un essai de phase 1
AU, Suisse et PRINCETON, New Jersey--(BUSINESS WIRE)--Araris Biotech AG, société développant un portefeuille différencié de thérapies par conjugués anticorps-médicament (« ADC »), et Taiho Oncology, Inc., société développant et commercialisant de nouveaux traitements pour les hémopathies malignes et les tumeurs solides, toutes deux membres du groupe Taiho, ont annoncé aujourd'hui que, dans le cadre d'un essai clinique de phase 1, le premier patient avait reçu une dose d'ARC-02, un conjugué anti...
-
Araris Biotech AG und Taiho Oncology geben die Verabreichung der ersten Dosis an einen Patienten in der Phase-1-Studie mit ARC-02 bekannt, einem neuartigen ADC zur Behandlung des Non-Hodgkin-Lymphoms
AU, Schweiz & PRINCETON, New Jersey--(BUSINESS WIRE)--Die Araris Biotech AG, ein Unternehmen, das eine differenzierte Pipeline von Therapien auf Basis von Antikörper-Wirkstoff-Konjugaten („ADCs“) vorantreibt, sowie Taiho Oncology, Inc., ein Unternehmen, das neuartige Therapien für hämatologische Malignome und solide Tumoren entwickelt und vermarktet – beide Unternehmen gehören zur Taiho-Gruppe –, gaben heute bekannt, dass der erste Patient im Rahmen einer klinischen Phase-1-Studie mit ARC-02, e...
-
Beazer Homes Announces Closing of Offering of $400 Million Senior Unsecured Notes due 2032
ATLANTA--(BUSINESS WIRE)--Beazer Homes USA, Inc. (NYSE: BZH) (the “Company”) announced today the completion of its previously-announced offering of $400 million aggregate principal amount of 8.000% Senior Unsecured Notes due 2032 (the “Notes”). The Notes were offered in a private offering that was exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The net proceeds of the offering will be used to finance the redemption of the Company’s 5.8...
-
ICON Reports First Quarter 2026 Results
DUBLIN--(BUSINESS WIRE)--ICON Reports First Quarter 2026 Results...
-
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
BOSTON--(BUSINESS WIRE)--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial...
-
Samenvatting: Veristat versterkt biostatistiek, advies bij ontwikkeling van geneesmiddelen en peoplemanagement om groei in complexe klinische ontwikkeling te ondersteunen
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--VeristatTM, een internationale CRO (Clinical Research Organization) en consultancy gespecialiseerd in complexe studies, maakte vandaag vier aanwervingen van strategische kaderleden bekend ter bevordering van zijn missie om de goedkeuring te versnellen van nieuwe therapieën in de domeinen van complexe ziekten, waaronder cel- en gentherapie, oncologie en zeldzame aandoeningen. Verder bouwend op zijn 30-jarige grondslag in biostatistiek en de recente overname...
-
Riassunto: Veristat rafforza la biostatistica, la consulenza per lo sviluppo dei farmaci e la leadership delle persone per sostenere la crescita nello sviluppo clinico complesso
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--VeristatTM , organizzazione di ricerca clinica (CRO) internazionale e società di consulenza specializzata in studi complessi, oggi ha annunciato quattro assunzioni strategiche ai vertici aziendali che promuovono la sua missione di accelerare nuove approvazioni terapeutiche nell'ambito di patologie complesse, tra cui citoterapia e terapia genica, oncologia e malattie rare. Grazie alla sua esperienza trentennale nella biostatistica e la sua recente acquisizio...
